High Detection Rate of HIV Drug Resistance Mutations among Patients Who Fail Combined Antiretroviral Therapy in Manaus, Brazil
Table 1
Prevalence of ARV used at any time during treatment and current in use, prevalence of the most prevalent DRMs to each ARV class in relation to the ARV current in use, and percentage of individuals with high ARV resistance related to the ARV used.
ARV
ARV used, (%)
ARV current in use, (%)
Drug resistance mutation, (%)
ARV high resistance level, (%)
M184I/V
K70E/R
T215F/Y
Total NRTI
82/82 (100)
82/82 (100)
68/82 (82.9)
16/82 (19.5)
17/82 (20.7)
70/82 (85.3)
3TC
82/82 (100)
76/82 (92.6)
68/82 (82.9)
TDF
70/82 (85.3)
69/82 (84.1)
6/70 (8.5)
AZT
41/82 (50.0)
5/82 (6.0)
9/41 (21.9)
K103N/S
V106A/I/M
P225H
Total NNRTI
71/82 (86.5)
48/82 (58.5)
51/71 (71.8)
11/71 (15.4)
15/71 (21.1)
64/71 (90.1)
EFV
71/82 (86.5)
52/82 (63.4)
64/71 (90.1)
V82A/L/M
I54L/M/V
M46L/I
Total PI
46/82 (50.0)
26/82 (31.7)
5/46 (10.8)
5/46 (10.8)
4/46 (8.6)
6/46(13.0)
LPV
18/82 (21.9)
1/82 (1.2)
2/18 (11.1)
ATZ/r
24/82 (29.2)
19/82 (23.1)
4/24 (16.6)
DRV
6/82 (7.3)
4/82 (4.8)
0 (0)
ARVs: 3TC: lamivudine; EFV: efavirenz; TDF: tenofovir; AZT: zidovudine; AZT/r: atazanavir/ritonavir; DRV: darunavir; LPV: lopinavir; PI: protease inhibitors. ARV resistance inputted according to high resistance level in the Stanford HIV Drug Resistance database (https://hivdb.stanford.edu/).
